Information Provided By: 
Fly News Breaks for August 18, 2017
TSRO, AZN, CLVS
Aug 18, 2017 | 07:23 EDT
Leerink analyst Michael Schmidt lowered his price target for Clovis Oncology (CLVS) to $107 after competitor AstraZeneca (AZN) received a broad label for PARP inhibitor Lynparza as maintenance treatment following second line ovarian cancer therapy regardless of BRCA status. His new target reflects a three-way market split among Clovis' Rubraca, Tesaro's (TSRO) Zejula and Lynparza in second line ovarian cancer maintenance. The analyst, however, believes Clovis remains attractively valued and he keeps an Outperform rating on the shares.
News For CLVS;AZN;TSRO From the Last 2 Days
AZN
Apr 18, 2024 | 09:41 EDT
Unusual total active option classes on open include: Wrap Technologies (WRAP), AstraZeneca (AZN), JetBlue (JBLU), United Continental (UAL), Taiwan Semi (TSM), Nokia (NOK), EBay (EBAY), Maplebear Inc (CART), Airbnb (ABNB), and UnitedHealth (UNH).
